

**Table 2.** Studies reporting neoadjuvant treatment of advanced NETs

Author, year	No of pts <sup>‡</sup>	Disease characteristics	Induction therapy	Comments	Follow-up
1 Sorbye et al, 2007 <sup>25</sup>	1	Pancreatic NEC, liver metastasis	Etoposide plus cisplatin	Partial response. R0 resection, no primary tumor found in pancreatectomy specimen	Adjuvant therapy 5 years - free of disease
2 Kwekkeboom et al, 2008 <sup>30</sup>	4/310	Non-functioning pNETs	PRRT ( <sup>177</sup> Lu-octreotate)	Partial response. R0 resection. One died postoperatively from complications	nr
3 Kaemmerer et al, 2009 <sup>24</sup>	1	Pancreatic NEC	PRRT ( <sup>90</sup> Y-DOTA-TATE)	Partial response. R0 resection	18 months - free of disease
4 Stoeltzing et al, 2010 <sup>31</sup>	1	Resected pNET, bilobular liver metastases	PRRT ( <sup>90</sup> Y-DOTA-TOC)	Partial response. R0 resection of liver metastases	12 months - free of disease
5 Sato et al, 2010 <sup>27</sup>	1	pNET, multiple liver metastases	S-1	Partial response (primary tumor)- complete response (liver metastases). R0 resection.	6 months - free of disease
6 Sowa-Staszczak et al, 2011 <sup>33</sup>	2/6	pNETs, 1 with liver metastases	PRRT ( <sup>90</sup> Y-DOTA-TATE)	Partial response (primary tumor). R2 resection Partial response (primary tumor) - complete response (liver metastases). R0 resection	nr
7 Lessing et al, 2011 <sup>26</sup>	3	NECs (2 duodenum, 1 rectosigmoid)	Etoposide, cisplatin	Partial response. R0 resection Partial response. R0 resection Complete response. No tumor at exploration	18 months – free of disease 5 months – recurrence/death 12 months – recurrence
8 Devata et al, 2012 <sup>29</sup>	1	pNET	Capecitabine plus temozolomide	Partial response. R0 resection	3 months - free of disease
9 Barber et al, 2012 <sup>34</sup>	1/5	pNET	PRCRT ( <sup>177</sup> Lu-octreotate plus 5-FU)	Partial response. R0 resection	12 months – free of disease
10 Lee et al, 2013 <sup>35</sup>	1/9	pNET	RT	Partial response. R0 resection	5 years – free of disease
11 Dumont et al, 2015 <sup>28</sup>	28/42	pNETs G1/2 with segmental portal hypertension	Chemotherapy (5-FU, streptozocin, doxorubicin, cisplatin, etoposide, oxaliplatin)	No radiological improvement in SPH signs. 13 R0, 6 R1 and 9R2 resections. Incomplete resections due to metastatic disease. All primary tumors resected	5-year overall survival [R0] vs [R1/R2/no resection]: 78% vs 55% (p=0.227)
12 Ezzidin et al, 2012 <sup>32</sup>	1	pNET with liver metastases	PRRT ( <sup>177</sup> Lu-octreotate)	Partial response. R0 resection, almost complete regression of liver metastases	22 months – complete local remission

NECs: neuroendocrine carcinoma(s); pNETs: pancreatic neuroendocrine tumor(s); PRRT: peptide receptor radionuclide therapy; PRCRT: peptide receptor chemoradionuclide therapy; nr: not reported; RT: radiotherapy.

<sup>‡</sup>Patients that underwent surgical exploration following neoadjuvant therapy/patients included in the study.